Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

BVS
Bioventus Inc. Class A Common Stock
stock NASDAQ

At Close
Jul 31, 2026 3:59:56 PM EDT
13.17USD-0.076%(-0.01)774,019
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 31, 2026 8:00:30 AM EDT
13.51USD+2.504%(+0.33)204
After-hours
Jul 31, 2026 4:17:30 PM EDT
13.10USD-0.532%(-0.07)68,538
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
07:18AM EST  Bioventus Sees Prelim. Q4 Revenue $128.5M-$131.5M vs $124.56M Est.; Sees Prelim. FY21 Revenue $429M-$432M vs $429.33M Est.   Benzinga
07:17AM EST  Bioventus Sees Q4 Sales $128.5M-$131.5M Vs. $124.56M Est., FY21 Sales $429M-$432M Vs. $429.33M Est.   Benzinga
07:00AM EST  Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, announced today preliminary revenue results for the fourth quarter and full-year 2021.   GlobeNewswire Inc
Dec 28, 2021
07:00AM EST  Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference via webcast on Wednesday, January 12, 2022, at 5:15 p.m. ET.   GlobeNewswire Inc
Dec 21, 2021
09:25AM EST  Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Companys Board of Directors, effective January 1, 2022.   GlobeNewswire Inc
Dec 20, 2021
08:37AM EST  Bioventus Reports FDA Granted 510(k) Clearance For Co.'s neXus BonScalpel Access Handpiece   Benzinga
08:34AM EST  Bioventus Receives US FDA Clearance For BoneScalpel Access   Benzinga
08:30AM EST  Bioventus Receives US FDA Clearance for BoneScalpel   GlobeNewswire Inc
Nov 18, 2021
08:49AM EST  Bioventus To Expand Operations And Manufacturing In Memphis   Benzinga
08:45AM EST  Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, has signed a lease agreement to double its current operations and manufacturing space and relocate from its current facility in suburban Memphis. Bioventus expects to move its 116 employees into the new space in early Q3 of 2022 and add another 40 jobs in the next five years.   GlobeNewswire Inc
Nov 15, 2021
11:07AM EST  Morgan Stanley Reinstates Overweight on Bioventus, Announces $20 Price Target   Benzinga
11:02AM EST  Bioventus Announces Greg Anglum Is Transitioning From His Role As Senior Vice President And Chief Financial Officer   Benzinga
07:30AM EST  Bioventus Announces Chief Financial Officer Transition Plan   GlobeNewswire Inc
Nov 9, 2021
11:31AM EST  Bioventus Raises FY21 Sales Guidance From $405M-$415M To $425M-$430M Vs. $410.24M Est.   Benzinga
11:31AM EST  Bioventus Q3 EPS $0.25 Beats $0.14 Estimate, Sales $108.89M Beat $102.23M Estimate   Benzinga
11:25AM EST  Earnings Scheduled For November 9, 2021   Benzinga
07:00AM EST  Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three and nine months ended October2, 2021.   GlobeNewswire Inc
Nov 1, 2021
08:30AM EDT  Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, has appointed Sharon Klugewicz as Senior Vice President, Quality and Regulatory Affairs. In this role, she will be responsible for all regulatory and quality functions globally, facilitating strong alignment across commercial, operations and R&D teams.   GlobeNewswire Inc
Oct 29, 2021
08:25AM EDT  Bioventus Completes the Acquisitionof Misonix   GlobeNewswire Inc
Oct 27, 2021
04:15PM EDT  Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, today announced that third quarter of fiscal year 2021 financial results will be released before the market opens on Tuesday, November 9, 2021.   GlobeNewswire Inc
Oct 26, 2021
04:47PM EDT  Bioventus, Misonix Reports Shareholders Approve Deal   Benzinga
Oct 18, 2021
08:00AM EDT  BIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of   GlobeNewswire Inc
Sep 20, 2021
08:30AM EDT  DUROLANE Among High-Molecular Weight Hyaluronic Acid   GlobeNewswire Inc
Sep 2, 2021
04:01PM EDT  Misonix, Inc. (Nasdaq: MSON) (Misonix or the Company), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below:   GlobeNewswire Inc
Aug 30, 2021
07:35AM EDT  Bioventus To Make $50M Escrow Payment Pursuant To Option And Equity Purchase Agreement With CartiHeal   Benzinga
07:30AM EDT  Bioventus Proceeds with Option Structure Agreement with CartiHeal   GlobeNewswire Inc
Aug 25, 2021
04:05PM EDT  Bioventus Invests in Trice Medical Minimally Invasive Technologies   GlobeNewswire Inc
05:12AM EDT  FDA Accelerates Review of Novartis Stamp Inhibitor Asciminib   Benzinga
Aug 23, 2021
08:30AM EDT  Dave Crawford Joins Bioventus asVice President,   GlobeNewswire Inc
Aug 19, 2021
06:31AM EDT  SV Health Investors Announces Three Realizations in its Growth Equity Portfolio   PR Newswire
Aug 10, 2021
04:36PM EDT  Bioventus Sees FY21 Sales $405M-$415M vs $400.94M Est.   Benzinga
04:36PM EDT  Bioventus Q2 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $109.80M Beat $97.64M Estimate   Benzinga
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
04:05AM EDT  Earnings Scheduled For August 10, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Jul 30, 2021
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
07:02AM EDT  Bioventus Scoops Up Misonix In $518M Stock & Cash Deal; Raises FY21 Sales Outlook   Benzinga
Jul 29, 2021
04:10PM EDT  Bioventus Announced It Has Entered Into A Definitive Agreement To Acquire Misonix In A Cash-And-Stock Transaction. Misonix Stockholders Will Receive Either 1.6839 Shares Of Bioventus Class A Common Stock Or $28 In Cash Without Interest Per Held Share.   Benzinga
04:07PM EDT  Misonix, Bioventus Board Have Approved Merger Between Companies For ~$518M; Misonix Shareholders Will Have Right To Elect To Receive For Each Share Either 1.6839 Shares Of Bioventus Or $28/Share In Cash   Benzinga
04:05PM EDT  Bioventus Raises FY21 Sales Guidance From $406M To $405M-$415M vs $400.9M EStimate   Benzinga
04:01PM EDT  Bioventus Sees Q2 Sales $108M-$110M vs $97.6M Estimate   Benzinga
Jul 27, 2021
04:15PM EDT  Senior management of Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12 at 3:30 p.m. ET and the Morgan Stanley Virtual Global Healthcare Conference on Friday, September 10 at 9:30 a.m. ET. Both events are virtual conferences.   GlobeNewswire Inc
Jul 14, 2021
04:07PM EDT  Bioventus Appoints Mary Kay Ladone to Board of Directors   GlobeNewswire Inc
Jul 13, 2021
08:39AM EDT  Bioventus Launches OSTEOAMP SELECT Flowable Nationwide   Benzinga
Jul 1, 2021
10:11AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021   Benzinga
05:45AM EDT  Goldman Sachs Downgrades Bioventus to Neutral, Lowers Price Target to $19   Benzinga
Jun 24, 2021
04:37PM EDT  Bioventus Reports Investment In Vaporox, No Terms Disclosed   Benzinga
04:37PM EDT  Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, has completed a minority investment in Vaporox, Inc., a developer of a highly innovative diabetic foot ulcer (DFU) wound healing therapy.   GlobeNewswire Inc
Jun 16, 2021
04:16PM EDT  Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, today announced that second quarter of fiscal year 2021 financial results will be released after the market closes on Tuesday, August 10, 2021.   GlobeNewswire Inc
May 25, 2021
09:07AM EDT  Bioventus Reports Human Placental Tissue Showed To Contain An Array Of Beneficial Growth Factors, Cytokines, Anti-Inflammatory Molecules   Benzinga
09:00AM EDT  Bioventus Study Shows Novel Placental Tissue Biologic Candidate   GlobeNewswire Inc
May 17, 2021
08:15AM EDT  Senior management of Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, will present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20 at 8:30 a.m. ET and the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9 at 11:20 a.m. ET. Both events are virtual conferences.   GlobeNewswire Inc
May 12, 2021
04:47PM EDT  Bioventus Raises FY21 Sales Guidance From $394M To $406M vs $381.54M Est.   Benzinga
04:47PM EDT  Bioventus Q1 EPS $(0.02) Misses $0.09 Estimate, Sales $81.80M Beat $76.54M Estimate   Benzinga
04:05PM EDT  Bioventus Inc. Reports First Quarter Results; Updates Full Year   GlobeNewswire Inc
04:22AM EDT  Earnings Scheduled For May 12, 2021   Benzinga
Apr 27, 2021
08:33AM EDT  Bioventus Announces First Commercial Shipment Of Bioness Integrated Therapy System Balance System   Benzinga
08:30AM EDT  Bioventus Announces First Commercial Shipment of the   GlobeNewswire Inc
Apr 19, 2021
10:11AM EDT  Morgan Stanley Maintains Overweight on Bioventus, Raises Price Target to $19   Benzinga
Apr 12, 2021
04:05PM EDT  Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, today announced that first quarter of fiscal year 2021 financial results will be released after the market closes on Wednesday, May 12, 2021.   GlobeNewswire Inc
Mar 30, 2021
05:43PM EDT  Bioventus Acquires Bioness For $45M In Up-Front Consideration With Up To $65M Of Contingent Consideration Related To Achievement Of Certain Key Milestones   Benzinga
05:42PM EDT  Bioventus Acquires Bioness, Inc.   GlobeNewswire Inc
Mar 25, 2021
04:12PM EDT  Bioventus Sees FY21 Adj. EBITDA $79M-$83M, Net Sales $360M-$372M   Benzinga
04:11PM EDT  Bioventus Q4 EPS $0.10, Sales $98.59M Beat $98.12M Estimate   Benzinga
04:05PM EDT  Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, today reported financial results for the fourth quarter and year ended December 31, 2020. This press release presents historical results, for the periods presented, of Bioventus, LLC, the predecessor of Bioventus Inc. for financial reporting purposes.   GlobeNewswire Inc
04:03AM EDT  Earnings Scheduled For March 25, 2021   Benzinga
Mar 11, 2021
09:12AM EST  Bioventus Says First Patients Enrolled In Phase 1 Clinical Trial Of MOTYS For Treatment Of Knee OA   RTTNews
09:03AM EST  Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS (PTP-001) for the Treatment of Knee OA   Benzinga
09:00AM EST  Bioventus Reports First Patients Enrolled in Phase 1 Clinical   GlobeNewswire Inc
Mar 8, 2021
10:27AM EST  Canaccord Genuity Initiates Coverage On Bioventus with Buy Rating, Announces Price Target of $23   Benzinga
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021   Benzinga
08:10AM EST  Morgan Stanley Initiates Coverage On Bioventus with Overweight Rating, Announces Price Target of $18   Benzinga
07:59AM EST  JP Morgan Initiates Coverage On Bioventus with Overweight Rating, Announces Price Target of $17   Benzinga
05:54AM EST  Goldman Sachs Initiates Coverage On Bioventus with Buy Rating, Announces Price Target of $19   Benzinga
Mar 4, 2021
09:00AM EST  Larry Chen Joins Bioventus as Managing Director, China and Asia   GlobeNewswire Inc
Mar 1, 2021
04:05PM EST  Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, today announced that fourth quarter and fiscal year 2020 financial results will be released after the market closes on Thursday, March 25, 2021.   GlobeNewswire Inc
Feb 26, 2021
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
Feb 24, 2021
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
Feb 19, 2021
07:25AM EST  The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko   Benzinga
Feb 17, 2021
07:27AM EST  The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal   Benzinga
Feb 11, 2021
12:32PM EST  Bioventus Shares Open For Trade At $15.10; IPO Priced At $13/Share   Benzinga
Feb 10, 2021
11:10PM EST  Bioventus Announces Pricing of Initial Public Offering   GlobeNewswire Inc
Feb 4, 2021
08:10AM EST  Bioventus Announces Launch of Initial Public Offering   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC